Who are Erdafitinib monotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): F14, JAB-21822, BPI-7711, HS-20137, HS-20089, TQB3616 capsules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/erdafitinib-monotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Erdafitinib monotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Erdafitinib monotherapy (Erdafitinib monotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FGFR inhibitor. Area: Oncology.

phase 2 FGFR inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Erdafitinib monotherapy (Erdafitinib monotherapy) — Spanish Oncology Genito-Urinary Group. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Erdafitinib monotherapy TARGET	Erdafitinib monotherapy	Spanish Oncology Genito-Urinary Group	phase 2	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4
F14	F14	Arthritis Innovation Corporation	marketed	FGFR inhibitor monoclonal antibody	FGFR (Fibroblast Growth Factor Receptor)
JAB-21822	JAB-21822	Allist Pharmaceuticals, Inc.	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)
BPI-7711	BPI-7711	Beta Pharma Shanghai	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)
HS-20137	HS-20137	Hansoh BioMedical R&D Company	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)
HS-20089	HS-20089	Hansoh BioMedical R&D Company	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)
TQB3616 capsules	TQB3616 capsules	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FGFR inhibitor class)

Hansoh BioMedical R&D Company · 3 drugs in this class
Haisco Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Allist Pharmaceuticals, Inc. · 2 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Hanmi Pharmaceutical Company Limited · 2 drugs in this class
Eisai Inc. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Beta Pharma Shanghai · 1 drug in this class
Guangdong Raynovent Biotech Co., Ltd · 1 drug in this class
Caliway Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Erdafitinib monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/erdafitinib-monotherapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing